Smith & Wesson Brands, Inc. (0HEM)
London Exchange · UK · prices in USD · close of 21 Oct 2026
Key indicators
| Last close | USD 14.85 |
|---|---|
| 52-week range | 7.83 – 17.18 |
| Return, 1 month / 3 months | +6.7% / +2.1% |
| Return, 1 year / 3 years | +53.7% / +37.0% |
| Trend | Uptrend |
| RSI (14) | 62 |
| Volatility (1 year) | 41.8% |
| Worst drawdown (1 year) | -26.5% |
| Average daily value traded | 0.02M USD |
| Dividend yield | 3.5% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Smith & Wesson Brands is an American firearms manufacturer based in the United States. It makes handguns, rifles and related shooting products, along with accessories and outdoor gear, and sells them under brands including Smith & Wesson and Thompson/Center Arms. Its customers include law enforcement agencies, military buyers, sport shooters, hunters and retailers that stock firearms and shooting supplies. The company designs and builds its products at its own manufacturing facilities and distributes them through dealers and distributors.
The shares are listed on the London Exchange in UK under the code 0HEM, and the price on this page is in US dollars (USD). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Smith & Wesson Brands, Inc. (0HEM) trades on the London Exchange in UK. It last closed at USD 14.85 on 21 October 2026.
Its price-based Market X-Ray is 55 out of 100 (a fair price profile), ranking 1,750 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 53.7% and over the last three months it rose 2.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 64 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 9.3% | ||
| From 52-week high | -9.6% | ||
| Momentum | 66 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 2.1% | ||
| 6-month return | 2.5% | ||
| 12-month return, skipping the last month | 44.0% | ||
| Stability (higher is calmer) | 47 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 41.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -26.5% | ||
| Liquidity | 16 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.02M USD | ||
| Zero-volume days | 0.0% | ||
| Income | 81 · Strong | Dividend is high and has been paid regularly. | |
| Dividend yield | 3.5% | ||
| Years with dividends | 6 |
Strengths
- Income: Dividend is high and has been paid regularly.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +4.8% |
|---|---|
| 1 month | +6.7% |
| 3 months | +2.1% |
| 6 months | +2.5% |
| 1 year | +53.7% |
| 3 years | +37.0% |
| 5 years | – |
Signals
| 50-day / 200-day average | 13.77 / 13.59 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.45 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 17 Sep 2026 | USD 0.1300 |
| 1 Jul 2026 | USD 0.1300 |
| 19 Mar 2026 | USD 0.1300 |
| 18 Dec 2025 | USD 0.1300 |
| 18 Sep 2025 | USD 0.1300 |
| 7 Jul 2025 | USD 0.1300 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.